Showing results (211-220 of 491) with videos related to
Sort By:
Pageof 50
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 2. Design, synthesis, and evaluation of a novel series of phenyl oxazole derivativesK Takeuchi, T J Kohn, D E Mais, et al.European Journal of Immunology|November 1, 1991
Signaling by vascular cell adhesion molecule-1 (VCAM-1) through VLA-4 promotes CD3-dependent T cell proliferationL C Burkly, A Jakubowski, B M Newman, et al.Journal of Thrombosis and Haemostasis : JTH|April 26, 2007
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metaboliteA Sugidachi, T Ogawa, A Kurihara, et al.Naunyn-Schmiedeberg'S Archives of Pharmacology|October 16, 2008
S-nitroso human serum albumin given after LPS challenge reduces acute lung injury and prolongs survival in a rat model of endotoxemiaA Jakubowski, N Maksimovich, R Olszanecki, et al.Blood|July 15, 1997
Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia linesA König, L Wrazel, R P Warrell, et al.Transplant Infectious Disease : an Official Journal of the Transplantation Society|May 22, 2007
Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantationN G Almyroudis, A Jakubowski, D Jaffe, et al.Platelets|June 7, 2011
Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonismJoseph A Jakubowski, Chunmei Zhou, Blaine Egan, et al.International Journal of Toxicology|June 14, 2012
Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agentLorrene A Buckley, Atsushi Sanbuissho, James J Starling, et al.The American Journal of Medicine|September 1, 1986
Effect of alternate-day regular and enteric-coated aspirin on platelet aggregation, bleeding time, and thromboxane A2 levels in bleeding-time bloodM J Stampfer, J A Jakubowski, D Deykin, et al.Cancer|February 1, 1994
Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemiaP C Caron, M A Schwartz, M S Co, et al.Pageof 50